Amneal Pharmaceuticals Receives FDA Approval for PEMRYDI RTU, a Ready-to-Use Oncology Injectable

Amneal Pharmaceuticals has received 505(b)(2) New Drug Application (NDA) approval from the US Food and Drug Administration for PEMRYDI RTU, a ready-to-use presentation of pemetrexed for injection. The treatment is indicated in combination with pembrolizumab and platinum chemotherapy for initial treatment of patients with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK geno..